Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 40.26 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 32.34 | Oscillator | Neutral |
| Williams %R (14) | -65.83 | Oscillator | Neutral |
| MACD (12, 26, 9) | -1.69 (Hist 0.28) | Oscillator | Buy |
| Average Directional Index (14) | 25.39 (+DI 15.4 / -DI 26.3) | Trend | Strong Sell |
| EMA 20 | 30.52 | MA | Strong Sell |
| SMA 20 | 30.11 | MA | Sell |
| EMA 50 | 33.31 | MA | Strong Sell |
| SMA 50 | 35.22 | MA | Strong Sell |
| SMA 200 | 32.57 | MA | Strong Sell |
Current price $29.25
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 2, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 23, 26 | Leerink Partners | maintain | Outperform | Outperform |
| Sep 23, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Sep 22, 26 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Sep 22, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 10, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Aug 7, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 7, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 29, 26 | Wells Fargo | maintain | Overweight | Overweight |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 25, 26 | Lawver Teri L | officer: SVP & Chief Commercial Officer | A-Award | 90,000 @ $34.09 | $3.07M |
| Jun 25, 26 | Jimenez Freddy A. | officer: SVP & GENERAL COUNSEL | A-Award | 93,000 @ $34.09 | $3.17M |
| Jun 25, 26 | Young Diane C. | officer: SVP, CHIEF MEDICAL OFFICER | A-Award | 57,000 @ $34.09 | $1.94M |
| Jun 25, 26 | Heath-Chiozzi Margo | officer: SVP OF REGULATORY AFFAIRS | A-Award | 95,000 @ $34.09 | $3.24M |
| Jun 25, 26 | Martin Samuel Bates | officer: SVP AND CFO | A-Award | 93,000 @ $34.09 | $3.17M |
| Jun 25, 26 | Cavanaugh Sarah | officer: SVP OF CORP AFFAIRS & ADMIN. | A-Award | 95,000 @ $34.09 | $3.24M |
| Jun 25, 26 | Crowley Elizabeth | officer: SR. VP & CPDO | A-Award | 100,000 @ $34.09 | $3.41M |
| Jun 25, 26 | Pepin Ronald | officer: SR. VP & CBO | A-Award | 20,000 @ $34.09 | $681.8K |
FY2025 · 10-K disclosure
Stock news · updated daily
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Senti Biosciences (NASDAQ: SNTI - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Insider and Institutional Ownership 25.7% of Senti Biosciences
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $37.89, but opened at $36.60. Celldex Therapeutics shares last traded at $35.18, with a volume of 3,679,133 shares traded. Celldex Therapeutics News Roundup Here are the key news stories impacting Celldex Therapeutics
Celldex Therapeutics (NASDAQ: CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (CSU) who experience inadequate symptom control using H1-antihistamines, including those who are advanced therapy experienced or refractory.
Celldex Therapeutics NASDAQ: CLDX reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -1.06 | -0.94 | Beat 11.3% | $22.00K |
| May 7, 2026 | -1.15 | -1.18 | Miss -2.9% | $15.00K |
| Feb 25, 2026 | -1.00 | -1.22 | Miss -22.0% | $100.0K |
| Nov 10, 2025 | -0.88 | -1.01 | Miss -14.8% | — |
| Aug 7, 2025 | -0.86 | -0.85 | Beat 1.2% | $730.0K |
| May 8, 2025 | -0.75 | -0.81 | Miss -8.0% | $695.0K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13G/A | Oct 7, 2026 | 2026-10-07 11:47:10 | View |
| 8-K | Sep 22, 2026 | 2026-09-22 07:09:01 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 12:09:21 | View |
| SC 13G | Aug 14, 2026 | 2026-08-14 10:38:26 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 16:06:26 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 16:01:21 | View |
| 8-K | Jul 15, 2026 | 2026-07-15 16:07:43 | View |
| 4 | Jun 29, 2026 | 2026-06-29 16:21:58 | View |
| 4 | Jun 29, 2026 | 2026-06-29 16:21:16 | View |
| 4 | Jun 29, 2026 | 2026-06-29 16:20:30 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | CLDX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -6.7x | -14.6x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -7.1x | EPS est. -4.13 | In line |
| Price / Book | 3.2x | 4.1x | Discount |
| Price / Sales | 20508.8x | 591.6x | Elevated |
| EV / EBITDA | -7.6x | -15.1x | Discount |
| Return on equity | -52.4% | — | Weak |
| Gross margin | -56850.9% | -1636.1% | Above hist. |
| Debt / Equity | 0.01 | 0.01 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 16.56 | Safe zone |
Discounted cash flow model